Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/68549
Title: | Type1 Diabetes prevention in NOD mice by targeting DPPIV/CD26 is associated with changes in CD8+T effector memory subset |
Author: | Alonso, Nuria Julián, María Teresa Carrascal, Jorge Colobran, Roger Pujol-Autonell, Irma Teniente, Aina Fernández, Marco Antonio Miñarro Alonso, Antonio María Ruiz de Villa, Carmen Vives-Pi, Marta Puig Domingo, Manuel Rodriguez-Fernández, Silvia |
Keywords: | Diabetis Limfòcits Citologia Ratolins (Animals de laboratori) Diabetes Lymphocytes Cytology Mice (Laboratory animals) |
Issue Date: | 10-Nov-2015 |
Publisher: | Public Library of Science (PLoS) |
Abstract: | CD26 is a T cell activation marker consisting in a type II transmembrane glycoprotein with dipeptidyl peptidase IV (DPPIV) activity in its extracellular domain. It has been described that DPPIV inhibition delays the onset of type 1 diabetes and reverses the disease in non-obese diabetic (NOD) mice. The aim of the present study was to assess the effect of MK626, a DPPIV inhibitor, in type 1 diabetes incidence and in T lymphocyte subsets at central and peripheral compartments. Pre-diabetic NOD mice were treated with MK626. Diabetes incidence, insulitis score, and phenotyping of T lymphocytes in the thymus, spleen and pancreatic lymph nodes were determined after 4 and 6 weeks of treatment, as well as alterations in the expression of genes encoding β-cell autoantigens in the islets. The effect of MK626 was also assessed in two in vitro assays to determine proliferative and immunosuppressive effects. Results show that MK626 treatment reduces type 1 diabetes incidence and after 6 weeks of treatment reduces insulitis. No differences were observed in the percentage of T lymphocyte subsets from central and peripheral compartments between treated and control mice. MK626 increased the expression of CD26 in CD8+ T effector memory (TEM) from spleen and pancreatic lymph nodes and in CD8+ T cells from islet infiltration. CD8+TEM cells showed an increased proliferation rate and cytokine secretion in the presence of MK626. Moreover, the combination of CD8+ TEM cells and MK626 induces an immunosuppressive response. In conclusion, treatment with the DPPIV inhibitor MK626 prevents experimental type 1 diabetes in association to increase expression of CD26 in the CD8+ TEM lymphocyte subset. In vitro assays suggest an immunoregulatory role of CD8+ TEM cells that may be involved in the protection against autoimmunity to β pancreatic islets associated to DPPIV inhibitor treatment. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0142186 |
It is part of: | PLoS One, 2015, vol. 10, num. 11, p. e0142186-e0142186 |
URI: | http://hdl.handle.net/2445/68549 |
Related resource: | http://dx.doi.org/10.1371/journal.pone.0142186 |
ISSN: | 1932-6203 |
Appears in Collections: | Articles publicats en revistes (Genètica, Microbiologia i Estadística) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
655904.pdf | 1.06 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License